Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Trial of Auto CAR-T for Relapsed and Refractory Hematopoietic and Lymphoid Tumors in Children
NCT04610125Unknown
- Sponsor
- Senlang Bio
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of senl-103 in leukemia and lymphoma, sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Status: unknown.
02
Drugs
senl-103
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NCT04610125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610125.